Epidemiology of Lung Cancer Prognosis: Quantity and Quality of Life

Part of the Methods in Molecular Biology book series (MIMB, volume 471)


Primary lung cancer is very heterogeneous in its clinical presentation, histopathology, and treatment response; and like other diseases, the prognosis consists of two essential facets: survival and quality of life (QOL). Lung cancer survival is mostly determined by disease stage and treatment modality, and the 5-Year survival rate has been in a plateau of 15% for three decades. QOL is focused on life aspects that are affected by health conditions and medical interventions; the balance of physical functioning and suffering from treatment side effects has long been a concern of care providers as well as patients. Obviously needed are easily measurable biologic markers to stratify patients before treatment for optimal results in survival and QOL and to monitor treatment responses and toxicities. Targeted therapies toward the mechanisms of tumor development, growth, and metastasis are promising and actively translated into clinical practice. Long-term lung cancer (LTLC) survivors are people who are alive 5 Years after the diagnosis. Knowledge about the health and QOL in LTLC survivors is limited because outcome research in lung cancer has been focused mainly on short-term survival. The independent or combined effects of lung cancer treatment, aging, smoking and drinking, comorbid conditions, and psychosocial factors likely cause late effects, including organ malfunction, chronic fatigue, pain, or premature death among lung cancer survivors. New knowledge to be gained should help lung cancer survivors, their healthcare providers, and their caregivers by providing evidence for establishing clinical recommendations to enhance their long-term survival and health-related QOL.

Key words

Non-small cell lung cancer small cell lung cancer survival quality of life pharmaco-genomics gene expression profiling chemotherapy radiation therapy toxicity 


  1. 1.
    Mountain, C. F. (1997) Revisions in the international system for staging lung cancer. Chest111(6), 1710–17.CrossRefPubMedGoogle Scholar
  2. 2.
    Yang, P., Allen, M. S., Aubry, M. C., Wamp-fler, J. A., Marks, R. S., Edell, E. S., Thi-bodeau, S. N., Adjei, A. A., Jett, J., and Deschamps, C. (2005) Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997–2003. Chest128, 452–62.CrossRefPubMedGoogle Scholar
  3. 3.
    Nesbitt, J. C., Lee, J. S., Komaki, R. and Roth, J. A. (1997) Cancer of the lung, in Cancer Medicine (Holland, J. F., Frei, E., III, Bast, R. J., Kufe, D., Morton, D., and Weichselbaum, R., eds.), Williams & Wilkins, Baltimore, MD, pp. 1723–803.Google Scholar
  4. 4.
    Feld, R., Sagman, U., and LeBlanc, M. (1996) Staging and prognostic factors: Small cell lung cancer, in Lung Cancer: Principles and Practice (Pass, H. I., Mitchell, J. B., Johnson, D. H., and Turrisi, A. T., eds.), Lipincott-Raven Publishers, Philadelphia, PA, pp. 495–509.Google Scholar
  5. 5.
    Wozniak, A. J., and Gadgeel, S. M. (2007) Adjuvant treatment of non-small-cell lung cancer: how do we improve the cure rates further? Oncology21, 164–71.Google Scholar
  6. 6.
    Rubin, P., Brasacchio, R., and Katz, A. (2006) Solitary metastases: illusion versus reality. Semin. Radiat. Oncol.16, 120–30.CrossRefPubMedGoogle Scholar
  7. 7.
    Martini, N., and Melamed, M. R. (1975) Multiple primary lung cancers. J. Thorac. Cardiovasc. Surg.70, 606–12.PubMedGoogle Scholar
  8. 8.
    Scott, W. J. (2004) Metachronous lung cancer: the role of improved postoperative surveillance. J. Thorac. Cardiovasc. Surg.127, 633–35.CrossRefPubMedGoogle Scholar
  9. 9.
    Martini, N., Bains, M. S., Burt, M. E., Zakowski, M. F., McCormack, P., Rusch, V. W., and Ginsberg, R. J. (1995) Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J. Thorac. Cardiovasc. Surg.109(1), 120–29.CrossRefPubMedGoogle Scholar
  10. 10.
    The Lung Cancer Study Group (1993) Malignant disease appearing late after operation for T1 N0 non-small cell lung cancer. J. Thorac. Cardiovasc. Surg.106, 1053–58.Google Scholar
  11. 11.
    Immerman, S. C., Vanecko, R. M., Fry, W. A., Head, L. R., and Shields, T. W. (1981) Site of recurrence in patients with stages I and II carcinoma of the lung resected for cure. Ann. Thorac. Surg.32, 23–27.CrossRefPubMedGoogle Scholar
  12. 12.
    Martini, N., Rusch, V. W., Bains, M. S., Kris, M. G., Downey, R. J., Flehinger, B. J. and Ginsberg, R. J. (1999) Factors influencing ten-Year survival in resected stages I to IIIA non-small lung cancer. J. Thorac. Car-diovasc. Surg.117, 32–38.CrossRefGoogle Scholar
  13. 13.
    Colice, G. L., Rubins, J., and Unger, M. (2003) Follow-up and surveillance of the lung cancer patient following curative-intent therapy. Chest123,Google Scholar
  14. 14.
    Thomas, P., Rubinstein, L., and The Lung Cancer Study Group. (1990) Cancer Recurrence after resection: T1 N0 non-small cell lung cancer. Ann. Thorac. Surg.49, 242–47.CrossRefPubMedGoogle Scholar
  15. 15.
    Sugimura, H., Nichols, F. C., Yang, P., Allen, M. S., Deschamps, C., Cassivi, S. D., Williams, B. A., and Pairolero, P. C. (2007) Survival following recurrent non-small cell lung cancer after complete pulmonary resection. Ann Thorac. Surg.83, 409–18.CrossRefPubMedGoogle Scholar
  16. 16.
    Williams, B. A., Sugimura, H., Endo, C., Nichols, F. C., Cassivi, S. D., Allen, M. S., Pairolero, P. C., Deschamps, C., and Yang, P. (2006) Predicting postrecurrence survival among completely resected nonsmall-cell lung cancer patients. Ann.Thorac. Surg.81, 1021–27.CrossRefPubMedGoogle Scholar
  17. 17.
    Visbal, A. L., Williams, B. A., Nichols, F. C., Marks, R. S., Jett, J. R., Aubry, M. C., Edell, E. S., Wampfler, J. A., Molina, J. R., and Yang, P. (2004) Gender differences in non-small cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997– 2002.Ann. Thorac. Surg. 78(1), 209–15.CrossRefPubMedGoogle Scholar
  18. 18.
    Sun, Z., Aubry, M. C., Deschamps, C., Marks, R. S., Okuno, S. H., Williams, B. A., Sugimura, H., Pankratz, V. S. and Yang, P. (2006) Histologic grade is an independent prognostic factor for survival in non-small cell lung cancer: an analysis of 5018 hospital- and 712 population-based cases.J. Tho-rac. Cardiovasc. Surg. 131, 1014–20.CrossRefGoogle Scholar
  19. 19.
    Ebbert, J. O., Yang, P., Vachon, C. M., Vier-kant, R. A., Cerhan, J. R., Folsom, A. R., and Sellers, T. A. (2003) Lung cancer risk reduction after smoking cessation: observations from a prospective cohort of women.J. Clin. Oncol. 21(5), 921–26.CrossRefPubMedGoogle Scholar
  20. 20.
    Jatoi, A., Williams, B., Nichols, F. C., Marks, R. S., Aubry, M. C., Wampfler, J., Finke, E. E., and Yang, P. (2005) Is voluntary vitamin and mineral supplementation associated with better outcome in non-small cell lung cancer? results from the Mayo Clinic lung cancer cohort.Lung Cancer 49, 77–84.CrossRefPubMedGoogle Scholar
  21. 21.
    Jatoi, A., Williams, B. A., Marks, R., Nichols,F. C., Aubry, M. C., Wampfler, J., and Yang, P. (2005) Exploring vitamin and mineral supplementation and purported clinical effects in patients with small cell lung cancer: results from the Mayo Clinic lung cancer cohort.Nutr. Cancer 51, 7–12.CrossRefPubMedGoogle Scholar
  22. 22.
    Brundage, M. D., Davies, D., and Mackil-lop, W. J. (2002) Prognostic factors in non-small cell lung cancer. A decade of progress.Chest 122(3), 1037–57.CrossRefPubMedGoogle Scholar
  23. 23.
    Sun, Z., and Yang, P. (2006) Gene expression profiling on lung cancer outcome prediction: present clinical value and future premise.Cancer Epidemiol. Biomarkers Prev. 15, 2063–68.CrossRefPubMedGoogle Scholar
  24. 24.
    Yanagisawa, K., Shyr, Y., Xu, B. J., Massion, P. P., Larsen, P. H., White, B. C., Roberts, J. R., Edgerton, M., Gonzalez, A., Nadaf, S., Moore, J. H., Caprioli, R. M., and Carbone, D. P. (2003) Proteomic patterns of tumour subsets in non-small-cell lung cancer.Lancet 362, 433–39.CrossRefPubMedGoogle Scholar
  25. 25.
    Yanagisawa, K., Tomida, S., Shimada, Y., Yatabe, Y., Mitsudomi, T., and Takahashi, T. (2007) A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer.J. Natl. Cancer Inst. 99, 858–67.CrossRefPubMedGoogle Scholar
  26. 26.
    Saijo, N. (2006) Recent trends in the treatment of advanced lung cancer.Cancer 97, 448–52.CrossRefGoogle Scholar
  27. 27.
    Byrne, B. J., and Garst, J. (2005) Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer.Curr. Oncol. Rep. 7, 241–47.CrossRefPubMedGoogle Scholar
  28. 28.
    Shigematsu, H., and Gazdar, A. F. (2006) Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers.Int. J. Cancer.118, 257–62.CrossRefPubMedGoogle Scholar
  29. 29.
    Janne, P. A., Engelman, J. A., and Johnson, B. E. (2005) Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology.J. Clin. Oncol. 23, 3227–34.CrossRefPubMedGoogle Scholar
  30. 30.
    Calvo, E., and Baselga, J. (2006) Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors.J. Clin. Oncol. 24, 2158–63.CrossRefPubMedGoogle Scholar
  31. 31.
    Jain, R. K. (2003) Molecular regulation of vessel maturation.Nat. Med. 9, 685–93.CrossRefPubMedGoogle Scholar
  32. 32.
    Molina, J. R., Adjei, A. A., and Jett, J. R.(2006) Advance in chemotherapy of non-small cell lung cancer.Chest 130, 1211–19.CrossRefPubMedGoogle Scholar
  33. 33.
    Stinchcombe, T. E. and Socinski, M. A.(2007) Bevacizumab in the treatment of non-small-cell lung cancer.Oncogene 26, 3691–98.CrossRefPubMedGoogle Scholar
  34. 34.
    Ruttinger, D., WInter, H., van den Engel, N. K., Hatz, R. A., Schlemmer, M., Phola, H., Grutzner, S., Schendel, D. J., Fox, B. A., and Jauch, K. W. (2006) Immunotherapy of lung cancer: an update.Onkologie 29, 33–38.CrossRefPubMedGoogle Scholar
  35. 35.
    Blackhall, F. H., and Shepherd, F. A. (2007) Small cell lung cancer and targeted therapies.Curr. Opin. Oncol. 19, 103–08.CrossRefPubMedGoogle Scholar
  36. 36.
    Cross, D., and Burmester, J. K. (2006) Gene therapy for cancer treatment: past, present and future.Clin. Med. Res. 4, 218–27.CrossRefPubMedGoogle Scholar
  37. 37.
    Boulikas, T., and Vougiouka, M. (2003) Cisplatin and platinum drugs at the molecular level.Oncol. Rep. 10, 1163–682.Google Scholar
  38. 38.
    Rogatko, A., Babb, J. S., Wang, H., Slifker, M. J., and Hudes, G. R. (2004) Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trials.Clin. Cancer Res. 10, 4645–51.CrossRefPubMedGoogle Scholar
  39. 39.
    Di Maio, M., Gridelli, C., Gallo, C., Shepherd, F., Piantedosi, F., Cigolari, S., Manzi-one, L., Illiano, A., Barbera, S., Robbiati, S. F., Frontini, L., Piazza, E., Ianniello, G. P., Veltri, E., Castiglione, F., Rosetti, F., Gebbia, V., Seymour, L., Chiodini, P., and Perrone, F. (2005) Chemotherapy-induced neutro-penia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials.Lancet Oncol. 6, 669–77.CrossRefPubMedGoogle Scholar
  40. 40.
    Gurney, H. (2005) I don't underdose my patients... do I?Lancet Oncol.6, 637–38.CrossRefPubMedGoogle Scholar
  41. 41.
    Susman, E. (2004) Rash correlates with tumour respsone after cetuximab.Lancet Oncol. 5, 647.CrossRefPubMedGoogle Scholar
  42. 42.
    Gurney, H. (2002) How to calculate the dose of chemotherapy.Br. J. Cancer 86, 297–302.CrossRefGoogle Scholar
  43. 43.
    Rankin, E. M., Mill, L., Kaye, S. B., Atkinson, R., Cassidy, L., Cordiner, J., Cruick-shank, D., Davis, J. R., Duncan, I. D., Fullerton, W., Habeshaw, T., Kennedy, J., Kennedy, R., Kitchener, H., MacLean, A., Paul, J., Reed, N., Sarker, T., Soukop, M., et al. (1992) A randomised study comapring standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer.Br. J. Cancer 65, 275–81.PubMedGoogle Scholar
  44. 44.
    Poikonen, P., Saar to, T., Lundin, J., Joensuu, H., and Blomqvist, C. (1999) Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF.Br. J. Cancer 80, 1763–66.CrossRefPubMedGoogle Scholar
  45. 45.
    Ratain, M. J., and Relling, M. V. (2001) Gazing into a crystal ball-cancer therapy in the post-genomic era.Nat. Med. 7, 283– 85.CrossRefPubMedGoogle Scholar
  46. 46.
    Lord, P. G., and Papoian, T. (2004) Genom-ics and Drug Toxicity.Science 306, 57.CrossRefGoogle Scholar
  47. 47.
    Yang, P., Ebbert, J. O., Sun, Z., and Wein-shilboum, R. M. (2005) A role of the glu-tathione metabolic pathway in lung cancer treatment and prognosis: a review.J. Clin. Oncol. 24, 1761–69.CrossRefGoogle Scholar
  48. 48.
    Fuertes, M. A., Castilla, J., Alonso, C. and Perez, J. M. (2003) Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways.Curr. Med. Chem. 10, 257–66.PubMedGoogle Scholar
  49. 49.
    Rosell, R., Taron, M., Camps, C., and Lopez-Vivanco, G. (2003) Influence of genetic markers on survival in non-small cell lung cancer.Drugs Today (Barc) 39, 775–86.CrossRefGoogle Scholar
  50. 50.
    Zhou, W., Gurubhagavatula, S., Liu, G., Park, S., Neuberg, D. S., Wain, J. C., Lynch, T. J., Su, L., and Christiani, D. C. (2004) Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.Clin. Cancer Res. 10, 4939– 43.CrossRefPubMedGoogle Scholar
  51. 51.
    Gurubhagavatula, S., Liu, G., Park, S., Zhou, W., Su, L., Wain, J. C., Lynch, T. J., Neuberg, D. S., and Christiani, D. C. (2004) XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.J. Clin. Oncol. 22, 2594–601.CrossRefPubMedGoogle Scholar
  52. 52.
    Ryu, J. S., Hong, Y. C., Han, H. S., Lee, J. E., Kim, S., Park, Y. M., Kim, Y. C., and Hwang, T. S. (2004) Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.Lung Cancer 44, 311–6.CrossRefPubMedGoogle Scholar
  53. 53.
    Connell, P. P., Kron, S. J., and Weichselbaum, R. R. (2004) Relevance and irrelevance of DNA damage response to radiotherapy.DNA Repair (Amst) 3, 1245–51.CrossRefGoogle Scholar
  54. 54.
    Willers, H., Dahm-Daphi, J., and Powell, S. N. (2004) Repair of radiation damage to DNABr. J. Cancer 90, 1297–301.CrossRefPubMedGoogle Scholar
  55. 55.
    Ross, G. M. (2002) Inducation of cell death by radiotherapy.Endocr. Relat. Cancer 6, 41–44.CrossRefGoogle Scholar
  56. 56.
    Leslie, E. M., Deeley, R. G., and Cole, S. P. C. (2001) Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters.Toxicology 167, 3–23.CrossRefPubMedGoogle Scholar
  57. 57.
    Danesi, R., De Braud, F., Fogli, S., Di Paolo, A., and Del Tacca, M. (2001) Pharmacoge-netic determinants of anti-cancer drug activity and toxicity.Trends Pharmacol. Sci. 22, 420–26.CrossRefPubMedGoogle Scholar
  58. 58.
    Strange, R. C., Jones, P. W., and Fryer, A. A. (2000) Glutathione S-trnasferase: genetics and role in toxicology.Toxicol. Lett. 112– 113, 357–63.CrossRefPubMedGoogle Scholar
  59. 59.
    Eaton, D. L., and Bammler, T. K. (1999) Concise Review of the glutathione s-trans-ferases and their significance to toxicology.Toxicol. Sci. 49, 156–64.CrossRefPubMedGoogle Scholar
  60. 60.
    O'Brien, M. L., and Tew, K. D. (1996) Glu-tathione and Related Enzymes in Multidrug Resistance.Eur. J. Cancer 6, 967–78.CrossRefGoogle Scholar
  61. 61.
    Anonymous. (1995) The World Health Organization Quality of Life Assessment (WHOQOL). Position Paper from the World Health Organization.Soc. Sci. Med. 41, 1403–09.CrossRefGoogle Scholar
  62. 62.
    Bonomi, A. E., Patrick, D. L., Bushnell, D. M., and Martin, M. (2000) Validation of the United States' Version of the World Health Organization Quality of Life (WHOQOL) Instrument.J. Clin. Epidemiol.53, 1–12.CrossRefPubMedGoogle Scholar
  63. 63.
    Li, W. W. L., Lee, T. W. and Yim, A. P. C. (2004) Quality of life after lung cancer resection.Thorac. Surg. Clin. 14, 353–65.CrossRefPubMedGoogle Scholar
  64. 64.
    Ware, J. E., and Sherbourne, C. D. (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.Med. Care 30, 473–83.CrossRefPubMedGoogle Scholar
  65. 65.
    McHorney, C. A., Ware, J. E., and Raczek, A. E. (1993) The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs.Med. Care 31, 247–63.CrossRefPubMedGoogle Scholar
  66. 66.
    Bergman, B., and Aaronson, N. K. (1995) Quality-of-life and cost-effectiveness assessment in lung cancer.Curr. Opin. Oncol. 7, 138–43.CrossRefPubMedGoogle Scholar
  67. 67.
    Cella, D. F., Bonomi, A. E., Lloyd, S. R., Tulsky, D. S., Kaplan, E., and Bonomi, P. (1995) Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument.Lung Cancer 12, 199–200.CrossRefPubMedGoogle Scholar
  68. 68.
    Hollen, P. J., Gralla, R. J., Kris, M. G., and Cox, C. (1994) Quality of life during clinical trials: conceptual model for the Lung Cancer Symptom Scale (LCSS).Support. Care Cancer 2, 213–22.CrossRefPubMedGoogle Scholar
  69. 69.
    Montazeri, A., Gillis, C. H., and McEwen, J. (1998) Quality of life in patients with lung cancer. A review of literature from 1970–1995.Chest 113(2), 467–81.CrossRefPubMedGoogle Scholar
  70. 70.
    Ganz, P. A., Figlin, R. A., Haskell, C. M., La Soto, N., Siau, J., and The UCLA Solid Tumor Study Group. (1989) Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer.Cancer 63, 1271–78.CrossRefPubMedGoogle Scholar
  71. 71.
    Helsing, M., Bergman, B., Thaning, L., and Hero, U. (1998) Quality of Life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A mul-ticentre randomized phase III trial.Eur. J. Cancer.34(7), 1036–44.CrossRefPubMedGoogle Scholar
  72. 72.
    Silvestri, G., Pritchard, R., and Weich, H. G. (1998) Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews.Br. Med. J. 317, 771–75.Google Scholar
  73. 73.
    Karmakar, M. K., and Ho, A. M. (2004) Postthoracotomy pain syndrome.Thorac. Surg. Clin. 14, 345–52.CrossRefPubMedGoogle Scholar
  74. 74.
    Stavraky, K. M., Donner, A. P., Kincade, J. E., and Stewart, M. A. (1988) The effect of psychosocial factors on lung cancer mortality at one Year.J. Clin. Epidemiol.41, 75–82.CrossRefPubMedGoogle Scholar
  75. 75.
    Reck, M., von Pawel, J., Macha, H. N., Kaukel, E., Deppermann, K. M., Bonnet, R., Ulm, K., Hessler, S., and Gatzemeier, U. (2006) Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: Quality of life and 6-Years'-follow-up results from a randomised phase III trial.Lung Cancer 53, 67–75.CrossRefPubMedGoogle Scholar
  76. 76.
    Temel, J. S., Pirl, W. F., and Lynch, T. J. (2006) Comprehensive symptom management in patients with advanced-stage non-small-cell lung cancer.Clin. Lung Cancer 7, 241–49.CrossRefPubMedGoogle Scholar
  77. 77.
    Sugimura, H., and Yang, P. (2006) Long-term survivorship in lung cancer. A review.Chest 29, 1088–97.CrossRefGoogle Scholar
  78. 78.
    Institute, N. C. (ed.) (2002) SEER Cancer Statistics Review, 1973–1999. Bethesda, MD.
  79. 79.
    Winton, T. L., Livingston, R. B., Johnson, D., and et al. (2004) A prospective randomized trial of adjuvant vionrelbine (VIN) and cisplation (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10. 7018.Google Scholar
  80. 80.
    Strauss, G. M., Herndon, J., Maddaus, M. A., et al. (2004) Randomized clinical trial of adjuvant chemotherapy with paclitzxel and craboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633. 7019.Google Scholar
  81. 81.
    Jacoulet, P., Depierre, A., Moro, D., Riviere, A., Milleron, B., Quoix, E., Ranfaing, E., Anthoine, D., Lafitte, J. J., Lebeau, B., Kleis-bauer, J. P., F., M., Fournel, P., Zaegel, M., Leclerc, J. P., Garnier, G., Brambilla, E., and Capron, F. (1997) Long-term survivors of small-cell lung cancer (SCLC): a French mul-ticenter study. Groupe d'Oncologie de Langue Francaise.Ann. Oncol. 8(10), 1009–14.CrossRefPubMedGoogle Scholar
  82. 82.
    Ko, C. Y., Maggard, M., and Livingston, E. H. (2003) Evaluating health utility in patients with melanoma, breast cancer, colon cancer, and lung cancer: a nationwide, population-based assessment.J. Surg. Res. 114, 1–5.CrossRefPubMedGoogle Scholar
  83. 83.
    Johnson, B. E., Cortazar, P., and Chute, J. P. (1997) Second lung cancers in patients successfully treated for lung cancer.Semin. Oncol. 24, 492–99.PubMedGoogle Scholar
  84. 84.
    Johnson, B. E. (1998) Second lung cancers in patients after treatment for an initial lung cancer.J. Natl. Cancer Inst. 90(18), 1335–45.CrossRefPubMedGoogle Scholar
  85. 85.
    Tucker, M. A., Murray, N., Shaw, E. G., Ettinger, D. S., Mabry, M., Huber, M. H., Feld, R., Shepherd, F. A., Johnson, D. H., Grant, S. C., Aisner, J., and Johnson, B. E. (1997) Second primary cancers related to smoking and treatment of small-cell lung cancer.J. Natl. Cancer Inst. 89(23), 1782–88.CrossRefPubMedGoogle Scholar
  86. 86.
    Sarna, L., Evangelista, L., Tashkin, D., Padilla, G., Holmes, C., Brecht, M. L., and Grannis, F. (2004) Impact of respiratory symptoms and pulmonary function on quality of life of long-term survivors of non-small cell lung cancer.Chest 125(2), 439–45.CrossRefPubMedGoogle Scholar
  87. 87.
    Myers, J. N., O'Neil, K. M., Walsh, T. E., Hoffmeister, K. J., Venzon, D. J. and Johnson, B. E. (2005) The pulmonary status of patients with limited-stage small cell lung cancer 15 Years after treatment with chemotherapy and chest irradiation.Chest 128,326168.CrossRefPubMedGoogle Scholar
  88. 88.
    Pinto, B. M., Eakin, E., and Maruyama, N. (2000) Health behavior changes after a cancer diagnosis: what do we know and where do we go from here?Ann. Behav. Med. 22, 38–52.CrossRefPubMedGoogle Scholar
  89. 89.
    Gritz, E. R., Nisenbaum, R., Elashoff, R. E., and Holmes, E. C. (1991) Smoking behavior following diagnosis in patients with stage I non-small cell lung cancer.Cancer Causes Control 2, 105–12.CrossRefPubMedGoogle Scholar
  90. 90.
    Yang, P., Sugimura, H., Ebbert, J. O., Nichols, F. C., Kelemen, L. E., Worra, J. B., Stoddard, S. M., Johnson, M. E., and Sloan, J. A. (2004). Characteristics of long-term lung term lung cancer survivors. In: Department of Health and Human Services. National Cancer Institute, and American Cancer Society (eds.), Canon Survirorship: Pathways to Health After Treatment, pp. 51 Washington, DC.Google Scholar
  91. 91.
    Evangelista, L. S., Sarna, L., Brecht, M. L., Padilla, G., and Chen, J. (2003) Health perceptions and risk behaviors of lung cancer survivors.Heart Lung 32(2), 131–39.CrossRefPubMedGoogle Scholar
  92. 92.
    Sarna, L., Padilla, G., Holmes, C., Tashkin, D., Brecht, M. L. and Evangelista, L. (2002) Quality of life of long-term survivors of non-small-cell lung cancer.J. Clin. Oncol. 20(13), 2920–29.CrossRefPubMedGoogle Scholar
  93. 93.
    Yang, P., Sugimura, H., Sloan, J., Williams, B., Cassivi, S., Garces, Y., Sun, Z., Worra, J., Midthun, D., and Jatoi, A. (2005) Longitudinal evaluation of quality of life in long-term lung cancer survivors (Abstract), in 11th World Conference on Lung Cancer, Presidential Symposium, July 3–6, 2005, Barcelona, Spain.Lung Cancer 49, S4.CrossRefGoogle Scholar
  94. 94.
    Kaasa, S., Mastekaasa, A., and Lund, E. (1989) Prognostic factors for patients with inoperable non-small cell lung cancer, limited disease.Radiother. Oncol.15, 235–42.CrossRefPubMedGoogle Scholar
  95. 95.
    Aziz, N. M. (2002) Cancer survivorship research: challenge and opportunity.J. Nutr. 132, 3494S–503S.PubMedGoogle Scholar
  96. 96.
    Wilson, I. B., and Cleary, P. D. (1995) Linking clinical variables with health-related quality of life: A conceptual model of patient outcomes.Jama 273, 59–65.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Mayo Clinic, College of MedicineRochesterUSA

Personalised recommendations